Novel treatment approaches utilizing antibody-drug conjugates in breast cancer
Abstract Antibody-drug conjugates (ADCs) are rapidly changing the way we treat patients with breast cancer. Despite this progress, many unanswered questions remain regarding the sequencing of different ADCs with similar payloads, optimal combinations, drug design strategies to limit off-target toxic...
Saved in:
| Main Authors: | Andrew A. Davis, Jennifer Hesse, Patrícia M. R. Pereira, Cynthia X. Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00743-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-drug conjugates in breast cancer: advances and prospects
by: Zhiqiang Shi, et al.
Published: (2025-02-01) -
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
by: Liu Y, et al.
Published: (2025-01-01) -
Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01) -
Antibody-Drug Conjugates in the Treatment of Metastatic Breast Cancer: The Emerging Questions of Sequence and Resistance
by: Allan Relecom, et al.
Published: (2024-10-01) -
In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy
by: Víctor L. Cruz, et al.
Published: (2025-08-01)